SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.^® (Nasdaq: PTLA) today announced that the Company will participate in the following investor conferences in November and December:

• Credit Suisse’s 27^th Annual Healthcare Conference on Tuesday, November 13, 2018, at 2:50 p.m. Mountain Time in Scottsdale, AZ. The Company will participate in a fireside chat at the conference, which will be webcast live and available for replay from the Investor Relations section of Portola’s website at www.portola.com.
   
• Citi’s Global Healthcare Conference on Thursday, December 6, 2018, in New York, NY. The Company will conduct one-on-one meetings with institutional investors at this conference.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s two FDA-approved medicines are Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, and Bevyxxa^® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.